Clinical Fellowships
Alnylam Pharmaceuticals funds U.S. clinical fellowships to train physicians in diagnosing, treating, and researching Transthyretin-mediated Amyloidosis (ATTR) through structured, multidisciplinary programs.
Funder: Alnylam Pharmaceuticals
Due Dates (Anticipated): August 2026: Clinical Fellowships submission deadline (projected)
Funding Amounts: Up to $95,000 per institution for a one-year clinical fellowship; funds support salary and fellow benefits only.
Summary: Supports U.S. academic institutions in training physicians to diagnose, treat, and research Transthyretin-mediated Amyloidosis (ATTR) through structured clinical fellowships.
Key Information: Applicant institutions must have an established cardiology fellowship program and be ACGME-accredited.
Description
Alnylam Pharmaceuticals’ Clinical Fellowships provide funding to U.S. healthcare academic organizations to support educational clinical programs focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The program is designed to foster multidisciplinary collaboration, enhance physician training in the diagnosis, treatment, and research of ATTR, and accelerate the application of emerging science into patient-centered care. Funding is intended to cover salary and benefits for the fellow, with an emphasis on early disease recognition and optimized treatment pathways. Institutions applying must demonstrate the necessary infrastructure, faculty, and curriculum to deliver a successful fellowship.
